Healthy Volunteers, Pharmacokinetics of ASP1941
Conditions
Keywords
ASP1941
Brief summary
This is a study of the pharmacokinetic profile and safety and tolerability of ASP1941after repeat dosing and the effect of ASP1941 on glucose levels in non elderly and elderly healthy adult male and female subjects.
Interventions
DRUGASP1941
oral
DRUGPlacebo
oral
Sponsors
Astellas Pharma Global Development, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female, healthy non-elderly (age 18-45 years, inclusive) or healthy elderly (age 65 or over) * If female, subject is not pregnant or nursing, and uses medically acceptable contraceptive method to prevent pregnancy from screening until study discharge * Body weigh between 60 and 100kg and body Mass Index between 20 and 30kg/m2, inclusive * Negative urine screen for drugs of abuse, including alcohol and cotinine
Exclusion criteria
* History of type 1 or type 2 diabetes * Fasting plasma glucose level higher than 6.4mmol/L or hemoglobin A1c level higher than 6.2% * Presence of renal glucosuria and/or proteinuria * Clinically significant history of asthma, eczema, and or any other allergic condition. * Clinically significant history of upper gastrointestinal symptoms within the 4 weeks prior to admission to the clinical unit. * History of any clinically significant neurological, gastrointestinal, renal, hepatic, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that would preclude participation in the study. * History of multiple drug allergies or a known allergy or suspected hypersensitivity to the study drug or any chemically related derivatives of the study drug or any components of the formulation * Has hepatitis or a positive result to serology test for hepatitis A antibody Immunoglobulin M, hepatitis B surface antigen or hepatitis C virus at screening * Known to be positive for human immunodeficiency virus antibodies. * Donated one unit (450 mL) or more of blood or plasma within 60 days prior to the first dose of study medication. * Has a history of consuming more than an average of 2 ounces of alcohol-containing products per day or a history of alcoholism or drug/chemical abuse within the last 3 years. * Use of any tobacco or nicotine-containing products within 120 days prior to the first dose of study medication. * Taken any prescribed systemic or topical medication within 21 days prior to the first dose of study medication with the exception of contraceptives to prevent pregnancy. * Taken any systemic or topical over-the counter medication, complementary or alternative medications, e.g., vitamins, herbal, or nutritional supplements, with the exception of acetaminophen, within 10 days prior to the first dose of study medication. * Taken an investigational drug within 30 days of the first dose of study medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic profile of ASP1941 (urine): Aetau, Aetau%, Aelast, CLR | Day 18 at pre-dose and from 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, 72 to 96 hours post-dose | Cumulative amount of drug or glucose excreted into urine over the time interval between consecutive dosing (Aetau ), Fraction of drug or glucose excreted into urine (Aetau) in % over the time interval between consecutive dosing (Aetau%) |
| Number of adverse events (AEs) | Through Day 29 | — |
| Safety as assessed by vital signs, electrocardiogram (ECG), physical examination, and laboratory evaluations | Through Day 29 | — |
| Pharmacokinetic profile of ASP1941 (plasma):AUCtau, CL/F, Cmax, tmax, t1/2, Vz/F, PTR | Days 1 and 18 pre-dose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72 and 96 hours post-dose | Area under the curve over the time interval between consecutive dosing (AUCtau),Apparent total body clearance after extravascular dosing (CL/F), Maximum observed concentration (Cmax), Time to reach Cmax (Tmax), Terminal elimination half-life (t1/2), Apparent volume of distribution during the terminal phase after single or repeated extravascular dosing (Vz/F), Peak Trough Ratio (PTR) |
| Pharmacokinetic profile of ASP1941 (urine): Ae, Ae%, Aelast, Aelast%, Ae24, CLR | Day 1 at pre-dose and from 0 to 2, 2 to 4, 4 to 6, 6 to 8, 8 to 12, 12 to 24, 24 to 36, 36 to 48, 48 to 72, 72 to 96 hours post-dose | Cumulative amount of drug excreted into urine up to the ending time of the last collection period (Ae), Fraction of the drug excreted in urine (Ae) in % up to the ending time of last collection period (Ae%), Cumulative amount of drug or glucose excreted into urine up to the collection time of the last measurable amount (Aelast),Fraction of drug excreted into urine (Ae) in % up to the collection time of the last measurable concentration (Aelast% ), Fraction of glucose excreted into urine up to 24 hrs (Ae24), Renal clearance (CLR) |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacodynamic profile of urine glucose: Aelast and Aetau | Day 1 and Day 18 |
| Rate of glucose excretion per sampling interval | Day 1 and Day 18 |
| Rate of glucose excretion over 24 hours | Day 1 and Day 18 |
| Pharmacodynamic profile of blood glucose: Cmax and AUCtau | Day -1 at -24, -23.75, -23.5, -23, -22.5, -22, -21, -20, -18, -16, -12, -8 and 0 (predose) hours prior to dose on Day 1 and on Day 18 predose and at 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36, 48, 72, and 96 hours post-dose |
Countries
United States
Outcome results
None listed